Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol

• Published in: BMJ open Vol. 12; no. 4; p. e061421
• Main Authors: Bieri, Uwe, Scharl, Michael, Sigg, Silvan, Szczerba, Barbara Maria, Morsy, Yasser, Rüschoff, Jan Hendrik, Schraml, Peter Hans, Krauthammer, Michael, Hefermehl, Lukas John, Eberli, Daniel, Poyet, Cédric
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 18.04.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Adjuvants, Immunologic; Administration, Intravesical; Age groups; BCG Vaccine - therapeutic use; Biobanks; Bladder cancer; Cancer therapies; Consent; Disease; Female; Humans; IMMUNOLOGY; Immunotherapy; Inflammation; Male; MICROBIOLOGY; Microbiota; Models, Statistical; Observational studies; Observational Studies as Topic; ONCOLOGY; Patients; Prognosis; Prostate cancer; Surgery; Urinary Bladder Neoplasms - pathology; Urine; Urological tumours; Urology; Urological tumours; MICROBIOLOGY; IMMUNOLOGY; ONCOLOGY
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-061421

IntroductionThe human microbiota, the community of micro-organisms in different cavities, has been increasingly linked with inflammatory and neoplastic diseases. While investigation into the gut microbiome has been robust, the urinary microbiome has only recently been described. Investigation into the relationship between bladder cancer (BC) and the bladder and the intestinal microbiome may elucidate a pathophysiological relationship between the two. The bladder or the intestinal microbiome or the interplay between both may also act as a non-invasive biomarker for tumour behaviour. While these associations have not yet been fully investigated, urologists have been manipulating the bladder microbiome for treatment of BC for more than 40 years, treating high grade non-muscle invasive BC (NMIBC) with intravesical BCG immunotherapy. Neither the association between the microbiome sampled directly from bladder tissue and the response to BCG-therapy nor the association between response to BCG-therapy with the faecal microbiome has been studied until now. A prognostic tool prior to initiation of BCG-therapy is still needed.Methods and analysisIn patients with NMIBC bladder samples will be collected during surgery (bladder microbiome assessment), faecal samples (microbiome assessment), instrumented urine and blood samples (biobank) will also be taken. We will analyse the microbial community by 16S rDNA gene amplicon sequencing. The difference in alpha diversity (diversity of species within each sample) and beta diversity (change in species diversity) between BCG-candidates will be assessed. Subgroup analysis will be performed which will lead to the development of a clinical prediction model estimating risk of BCG-response.Ethics and disseminationThe study has been approved by the Cantonal Ethics Committee Zurich (2021-01783) and it is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. Study results will be disseminated through peer-reviewed journals and national and international scientific conferences.Trial registration numberNCT05204199.